RECURRENT LUNG NON-SMALL CELL CARCINOMA
Clinical trials for RECURRENT LUNG NON-SMALL CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT LUNG NON-SMALL CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT LUNG NON-SMALL CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for tough lung cancer
Disease control CompletedThis study tested a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a targeted therapy (selumetinib) in 40 people with advanced non-small cell lung cancer that had returned or spread. The goal was to find the safest dose and see if the combo could shrink…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Vitamin a derivative combined with immunotherapy shows promise in early lung cancer trial
Disease control CompletedThis early-phase trial is testing a combination of all-trans retinoic acid (ATRA), a substance made from vitamin A, and the immunotherapy drug atezolizumab in people with advanced non-small cell lung cancer that has spread or come back. The main goal is to find the safest dose an…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: Dwight Owen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for drug-resistant lung cancer: combo therapy tested in early trial
Disease control CompletedThis early-phase trial tested two experimental drug combinations in 37 people with advanced EGFR-mutant lung cancer that no longer responded to the targeted therapy osimertinib. The goal was to find safe, tolerable doses of alisertib or sapanisertib when given together with osime…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Proton beam doses put to the test for tough lung cancers
Disease control CompletedThis trial tested different doses of proton beam therapy combined with standard chemotherapy for people with stage 2-3 non-small cell lung cancer that cannot be surgically removed. The goal was to find the best radiation dose to control the cancer. Twenty participants received tr…
Matched conditions: RECURRENT LUNG NON-SMALL CELL CARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC